ArticlePublisher preview available

Do timing and severity of gestational COVID-19 impact perinatal and neonatal outcomes?

Authors:
  • Parc de Salut Mar, Hospital del Mar, Barcelona, Spain
To read the full-text of this research, you can request a copy directly from the authors.

Abstract

Objective To examine the relationship between gestational COVID-19 and perinatal-neonatal outcomes. Study design Prospective cohort study. Neonates born at Hospital del Mar (Barcelona) between 2020 and 2022 were classified into two cohorts according to their mother’s COVID-19 status during pregnancy. Prenatal and postnatal variables were compared between the COVID-19 and the control cohort, and depending on timing and severity of maternal infection. Results We included 2701 neonates and observed higher rates of respiratory distress (5.7% vs 3.3%, p = 0.044) and pathological jaundice (7.7% vs 4.1%, p = 0.007) in the COVID-19 cohort, without differences between trimesters. We did not find statistically significant differences in other perinatal outcomes. The logistic regression analyses showed that maternal COVID-19 was not a risk factor for prematurity (OR:1.23;CI:0.75–2.03; p = 0.407). Conclusions Infants born to mothers with COVID-19 during pregnancy in our hospital showed higher rates of respiratory distress and pathological jaundice, without increased rates of prematurity or other morbidities.
ARTICLE
Do timing and severity of gestational COVID-19 impact
perinatal and neonatal outcomes?
Júlia Candel-Pau
1,2
, Daniel Suqué-Tusell
1,2
, Sílvia Maya-Enero
1
, Carlos Ramon-Iglesias
1
, Beatriz Valle-del-Barrio
1
and
Maria Ángeles López-Vílchez
1
© The Author(s), under exclusive licence to Springer Nature America, Inc. 2024
OBJECTIVE: To examine the relationship between gestational COVID-19 and perinatal-neonatal outcomes.
STUDY DESIGN: Prospective cohort study. Neonates born at Hospital del Mar (Barcelona) between 2020 and 2022 were classied
into two cohorts according to their mothers COVID-19 status during pregnancy. Prenatal and postnatal variables were compared
between the COVID-19 and the control cohort, and depending on timing and severity of maternal infection.
RESULTS: We included 2701 neonates and observed higher rates of respiratory distress (5.7% vs 3.3%, p=0.044) and pathological
jaundice (7.7% vs 4.1%, p=0.007) in the COVID-19 cohort, without differences between trimesters. We did not nd statistically
signicant differences in other perinatal outcomes. The logistic regression analyses showed that maternal COVID-19 was not a risk
factor for prematurity (OR:1.23;CI:0.752.03; p=0.407).
CONCLUSIONS: Infants born to mothers with COVID-19 during pregnancy in our hospital showed higher rates of respiratory
distress and pathological jaundice, without increased rates of prematurity or other morbidities.
Journal of Perinatology; https://doi.org/10.1038/s41372-024-02179-9
INTRODUCTION
During the COVID-19 pandemic many questions were raised
concerning the SARS-CoV-2 infection impact on pregnant women
and their newborns. Although pregnant women were considered a
risk group for severe COVID-19, children were quickly reconsidered as
a group with low morbimortality [1,2]. Current evidence suggests that
vertical transmission of SARS-CoV-2 is possible, although rare [36].
Postnatal transmission is more frequent, but causes low morbimor-
tality [7] and its incidence can be reduced by following the
recommendations of the Spanish Society of Neonatology (SENEO)
[8]. On the other hand, there is still controversy regarding the perinatal
and neonatal impact of gestational COVID-19 [4]. Some authors report
similar perinatal and neonatal outcomes in COVID-19 affected and
non-affected pregnancies [911]. However, many other studies have
reported higher rates of caesarean section [1222]andprematurity
[1224], as well as higher admission rates to the neonatal intensive
care unit (NICU) among neonates born to mothers with gestational
COVID-19 [1318,22,23]. Moreover, increased risk of low Apgar
[14,21], stillbirth [14,23], low birth weight [13,14,16,18,22], and
hyperbilirubinemia [25,26] have also been described. Most of these
studies were conducted during the rst months of the pandemic, and
it has been hypothesized that the higher rates could be related to
iatrogenic practices [15]. Regarding other relevant adverse outcomes,
only one systematic review and meta-analysis has reported higher
rates of respiratory distress (RD) requiring support among neonates
born to mothers with COVID-19, without conrmed neonatal COVID-
19 infection but with a possible relation to prematurity with increased
rates of respiratory distress syndrome (RDS) [21].
Given that coexistence with COVID-19 is likely to become
permanent, increasing scientic evidence is crucial to guide
clinical decision-making. Current knowledge about COVID-19 in
the perinatal stage is scarce and studies addressing the relation-
ship between maternal infection and its perinatal and neonatal
impact are heterogeneous and yield contradictory results [4],
differing signicantly between countries [27].
We hypothesized that children born to mothers infected with
SARS-CoV-2 during pregnancy do not have worse perinatal or
neonatal outcomes than the rest of the population. The aim of this
study was to examine the clinical outcomes of neonates in a tertiary
hospital in Barcelona during the COVID-19 pandemic and their
relationship with maternal SARS-CoV-2 infection during pregnancy.
Considering the variation in biological events across trimesters of
pregnancy [17,28,29], we further aimed to analyze the inuence of
gestational timing of maternal SARS-CoV-2 infection and its severity
on perinatal and neonatal outcomes. This analysis included factors
such as trimester of infection, presence of active maternal infection
at delivery, and severity of maternal symptoms.
MATERIALS AND METHODS
This was a prospective cohort study conducted at Hospital del Mar in
Barcelona, a tertiary care centre with approximately 1400 deliveries per
year. All neonates born in this hospital between March 2020 and May 2022
and their mothers were included. Exclusion criteria were parentsrefusal to
participate in the study and transfer to another centre that prevented
follow-up.
Received: 17 July 2024 Revised: 6 November 2024 Accepted: 11 November 2024
1
Department of Neonatology, Service of Pediatrics, Hospital del Mar Barcelona, Universitat Pompeu Fabra, Passeig Marítim 25-29, 08003 Barcelona, Catalonia, Spain.
2
These
authors contributed equally: Júlia Candel-Pau, Daniel Suqué-Tusell email: jcandelpau@psmar.cat
www.nature.com/jp
Journal of Perinatology
1234567890();,:
Content courtesy of Springer Nature, terms of use apply. Rights reserved
ResearchGate has not been able to resolve any citations for this publication.
Article
Full-text available
Infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) in pregnancy are associated with the development of preeclampsia and fetal growth restriction (FGR). Recently, preeclampsia was linked to impaired maternal hemodynamic function. This retrospective study evaluated singleton pregnancies with COVID-19 during pregnancy and healthy pregnant controls matched for gestational age from November 2020 to March 2022. Non-invasive assessment of maternal hemodynamics by continuous wave Doppler ultrasound measurements (USCOM-1A® Monitor) and oscillometric arterial stiffness (Arteriograph) was performed. Overall, 69 pregnant women were included—23 women after COVID-19 during pregnancy and 46 healthy controls. While two women (8.7%) were admitted to the hospital due to COVID-19-related symptoms, none required intensive care unit admission or non-invasive/invasive ventilation. There were no statistically significant differences in the majority of hemodynamic parameters between the two cohorts. The prevalence of FGR was significantly higher in the COVID-19 during pregnancy group (9.5% vs. healthy controls: 0.0%; p = 0.036), especially in nulliparous women. No difference in angiogenic markers and neonatal outcomes were observed between pregnant women after COVID-19 and healthy controls. In conclusion, no significant differences in hemodynamic parameters or neonatal outcome were observed in women with COVID-19 during pregnancy. However, an increased prevalence of FGR could be described.
Article
Full-text available
In this systematic review and meta-analysis, we aimed to review the characteristics and outcomes of the newborns of Coronavirus disease 2019 (COVID-19) infected pregnant women. We conducted an online bibliographic search using the following electronic databases: MEDLINE via PubMed, Scopus, Web of Science, and Cochrane Central. Studies were deemed eligible if they recruited newborns from mothers with confirmed COVID-19 and reported the perinatal outcomes of neonatal COVID-19 cases. A total of 20 studies were included. Neonates born to mothers with positive COVID-19 results have been shown to have significantly lower birth weights (mean difference, MD = -48.54 g, p = 0.04), increased risks of fetal distress (odds ratio, OR = 1.76, p < 0.00001), respiratory distress (OR = 1.96, p = 0.006), premature birth (OR = 2.08, p < 0.00001), neonatal death (OR = 2.20, p = 0.004), and a lower 5-minute Apgar score (OR = 1.44, p = 0.02). Additionally, they were more likely to be admitted to the neonatal intensive care unit (NICU) (OR = 2.25, p = 0.007) and test positive for COVID-19 themselves (OR = 9.88, p = 0.03). However, other parameters, such as risks for malformations, mechanical ventilation, hypoglycemia, and sepsis, appeared to be comparable between the two groups. Maternal infection with COVID-19 during pregnancy is associated with several neonatal outcomes, some of which are adverse and others that do not show significant deviation from norms. While our meta-analysis clearly illustrates heightened risks associated with premature birth, reduced neonatal weight, and other challenges, it also emphasizes that not all neonatal outcomes can be directly attributed to maternal SARSCoV- 2 infection.
Article
Full-text available
Purpose: There is limited information on the clinical characteristics and prognosis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection during pregnancy. The clinical features and risk factors for hypoxemia development were investigated in pregnant women with coronavirus disease-2019 (COVID-19). Materials and methods: From August 2020 to February 2022, we performed a retrospective cohort study of 410 pregnant women with COVID-19. The clinical characteristics and prognoses were compared between pregnant COVID-19 patients requiring oxygen and those who did not. Results: Of 410 patients, 100 (24.4%) required oxygen therapy. Among them, fever [163 (52.6%) vs. 81 (81.0%), p<0.001] and cough [172 (56.4%) vs. 73 (73.0%), p=0.003] were more frequently observed than in non-oxygen group. The proportion of unvaccinated women was higher in oxygen group than in non-oxygen group [264 (85.2%) vs. 98 (98.0%), p=0.003]. During the Omicron wave, patients were more likely to have no oxygen requirement [98 (31.6%) vs. 18 (18.0%), p=0.009]. The risk of hypoxemic respiratory difficulty increased if SARS-CoV-2 infection occurred during the third trimester [adjusted odds ratio (aOR) 5.083, 95% confidence interval (CI): 1.095-23.593, p=0.038] and C-reactive protein (CRP) was elevated (≥1.0 mg/dL) at admission (aOR 5.878, 95% CI: 3.099-11.146, p<0.001). The risk was higher in unvaccinated patients (aOR 5.376, 95% CI: 1.193-24.390, p=0.028). However, the risk was lower in patients during the Omicron wave (aOR 0.498, 95% CI: 0.258-0.961, p=0.038). Conclusion: A quarter of SARS-CoV-2-infected women developed hypoxemic respiratory difficulty during pregnancy. SARS-CoV-2 infection during the third trimester, CRP elevation at admission, and no vaccination increased the risk of hypoxemia in pregnant women.
Article
Full-text available
Objectives To identify the association between maternal SARS-CoV-2 infection in pregnancy and individual neonatal morbidities and outcomes, particularly longer-term outcomes such as neurodevelopment. Design Systematic review of outcomes of neonates born to pregnant women diagnosed with a SARS-CoV-2 infection at any stage during pregnancy, including asymptomatic women. Data sources MEDLINE, Embase, Global Health, WHOLIS and LILACS databases, last searched on 28 July 2021. Eligibility criteria Case–control and cohort studies published after 1 January 2020, including preprint articles were included. Study outcomes included neonatal mortality and morbidity, preterm birth, caesarean delivery, small for gestational age, admission to neonatal intensive care unit, level of respiratory support required, diagnosis of culture-positive sepsis, evidence of brain injury, necrotising enterocolitis, visual or hearing impairment, neurodevelopmental outcomes and feeding method. These were selected according to a core outcome set. Data extraction and synthesis Data were extracted into Microsoft Excel by two researchers, with statistical analysis completed using IBM SPSS (Version 27). Risk of bias was assessed using a modified Newcastle-Ottawa Scale. Results The search returned 3234 papers, from which 204 were included with a total of 45 646 infants born to mothers with SARS-CoV-2 infection during pregnancy across 36 countries. We found limited evidence of an increased risk of some neonatal morbidities, including respiratory disease. There was minimal evidence from low-income settings (1 study) and for neonatal outcomes following first trimester infection (17 studies). Neonatal mortality was very rare. Preterm birth, neonatal unit admission and small for gestational age status were more common in infants born following maternal SARS-CoV-2 infection in pregnancy in most larger studies. Conclusions There are limited data on neonatal morbidity and mortality following maternal SARS-CoV-2 infection, particularly from low-income countries and following early pregnancy infections. Large, representative studies addressing these outcomes are needed to understand the consequences for babies born to women with SARS-CoV-2. PROSPERO registration number CRD42021249818.
Article
Full-text available
Introduction Despite a growing body of research on the risks of SARS-CoV-2 infection during pregnancy, there is continued controversy given heterogeneity in the quality and design of published studies. Methods We screened ongoing studies in our sequential, prospective meta-analysis. We pooled individual participant data to estimate the absolute and relative risk (RR) of adverse outcomes among pregnant women with SARS-CoV-2 infection, compared with confirmed negative pregnancies. We evaluated the risk of bias using a modified Newcastle-Ottawa Scale. Results We screened 137 studies and included 12 studies in 12 countries involving 13 136 pregnant women. Pregnant women with SARS-CoV-2 infection—as compared with uninfected pregnant women—were at significantly increased risk of maternal mortality (10 studies; n=1490; RR 7.68, 95% CI 1.70 to 34.61); admission to intensive care unit (8 studies; n=6660; RR 3.81, 95% CI 2.03 to 7.17); receiving mechanical ventilation (7 studies; n=4887; RR 15.23, 95% CI 4.32 to 53.71); receiving any critical care (7 studies; n=4735; RR 5.48, 95% CI 2.57 to 11.72); and being diagnosed with pneumonia (6 studies; n=4573; RR 23.46, 95% CI 3.03 to 181.39) and thromboembolic disease (8 studies; n=5146; RR 5.50, 95% CI 1.12 to 27.12). Neonates born to women with SARS-CoV-2 infection were more likely to be admitted to a neonatal care unit after birth (7 studies; n=7637; RR 1.86, 95% CI 1.12 to 3.08); be born preterm (7 studies; n=6233; RR 1.71, 95% CI 1.28 to 2.29) or moderately preterm (7 studies; n=6071; RR 2.92, 95% CI 1.88 to 4.54); and to be born low birth weight (12 studies; n=11 930; RR 1.19, 95% CI 1.02 to 1.40). Infection was not linked to stillbirth. Studies were generally at low or moderate risk of bias. Conclusions This analysis indicates that SARS-CoV-2 infection at any time during pregnancy increases the risk of maternal death, severe maternal morbidities and neonatal morbidity, but not stillbirth or intrauterine growth restriction. As more data become available, we will update these findings per the published protocol.
Article
Full-text available
Background: Vertical transmission of several viruses during pregnancy has been shown to cause adverse fetal outcomes. The question about the possibility of a similar outcome in association with SARS-CoV-2 has been raised in recently published articles. Indeed, the rate of transmission through the placenta to the fetus reported in women with COVID-19 has been shown to form a minority. The aim of this study was to explore the possible histopathological changes in the placenta of pregnant women with COVID-19 after delivery and those changes in the umbilical cord. Methods: A case-control study including a total of 50 full-term pregnant women with COVID-19 and 60 control pregnant females. Histopathological evaluation of placental tissues and umbilical cords were reported. Results: The main findings in the umbilical cord were increased thickness of vessels, thrombus formation, endothelins, and narrow lumen; except for the increased thickness of blood vessels, these findings were more frequently seen in women with COVID-19, in comparison with control women in a significant manner (p < 0.05). Increased thickness of blood vessels was more significantly observed in the control group compared to the COVID-19 group (p < 0.01). Findings of the placenta included avascular villi, fibrin, thrombosis, and meconium macrophage in various combinations. Except for fibrin as the sole findings, all other findings including combinations were more frequently encountered in the study group in comparison to the control group (p < 0.05). Conclusion: Pregnant women with COVID-19 have significant pathological alterations in the placenta and umbilical cord. These findings reflect the capability of SARS-CoV-2 in causing immunological reactions to the placenta, either directly or indirectly, and these pathologies may be linked to the higher rate of adverse neonatal outcomes and maternal admission to the intensive care unit.
Article
Objective: In this study, maternal and neonatal outcomes of pregnant women with positive severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) RNA tests were evaluated according to their symptomatic status. The clinical progression of SARS-CoV-2-positive pregnant women and the effect of coronavirus disease-2019 (COVID-19) on newborns was investigated. Material and methods: This retrospective cohort study was conducted at a tertiary pandemic hospital specializing in caring for pregnant women infected with SARS-CoV-2. We included patients with a positive SARS-CoV-2 polymerase chain reaction test at delivery, subdividing them into symptomatic and asymptomatic groups. Results: Two hundred and forty-nine patients were included in the study. The mean age of the pregnant women in the symptomatic group was higher than those in the asymptomatic group (p=0.001). The iatrogenic preterm birth rates in the symptomatic and asymptomatic groups were 43.37% and 8.43%, respectively (p<0.001). Cesarean section rate was higher in symptomatic group (p=0.01). Maternal death was significantly higher in symptomatic pregnant women (p<0.001). The neonatal intensive care unit admission rate was higher in symptomatic pregnant women (p<0.001). Conclusion: The maternal and fetal outcomes for mothers with symptomatic infections tend to be worse, highlighting the importance of careful management, good follow-up and the advisability of closer monitoring.
Article
OBJECTIVES To evaluate outcomes of neonates born to mothers with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection during pregnancy, the dynamics of placental transfer of maternal antibodies, and its persistence during infancy. METHODS Cohort study enrolling neonates born to mothers with SARS-CoV-2 infection in pregnancy. All infants were evaluated at birth. Those born to women with infection onset within 2 weeks before delivery were excluded from further analyses. Remaining infants underwent cerebral and abdominal ultrasound, fundoscopy evaluation, and were enrolled in a 12 month follow-up. Qualitative immunoglobulin G (IgG)/immunoglobulin M and quantitative IgG to S1/S2 subunits of spike protein were assessed in mother–neonate dyads within 48 hours postdelivery and during follow-up. RESULTS Between April 2020 and April 2021, 130 of 2745 (4.7%) neonates were born to mothers with SARS-CoV-2 infection in pregnancy, with 106 of 130 infections diagnosed before 2 weeks before delivery. Rates of preterm and cesarean delivery were comparable between women with and without infection (6% vs 8%, P = .57; 22% vs 32%, P = .06). No clinical or instrumental abnormalities were detected at birth or during follow-up. There was a positive correlation between maternal and neonatal SARS-CoV-2 IgG levels (r = 0.81, P < .001). Transplacental transfer ratio was higher after second-trimester maternal infections as compared with first and third trimester (P = .03). SARS-CoV-2 IgG level progressively decreased in all infants, with 89 of 92 (97%) infants seronegative at 6 months of age. CONCLUSIONS Clinical outcomes were favorable in all infants. Matching peak IgG level after infection and higher IgG transplacental transfer might result in the most durable neonatal passive immunity.